Ophthalmology

Patients With nAMD Maintain Vision on Aflibercept Biosimilar ABP 938

September 3rd 2025

By Skylar Jeremias

A new biosimilar for aflibercept shows similar efficacy and safety in treating neovascular age-related macular degeneration (nAMD), enhancing patient access to treatment.

Biosimilar Business Recap: Updates on Tocilizumab, Omalizumab, and Ranibizumab Products

August 13th 2025

By Skylar Jeremias

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ranibizumab.

Bevacizumab Biosimilar Fills Gap for Retinal Disease With Encouraging Safety Data

July 23rd 2025

By Skylar Jeremias

Real-world data confirm Mvasi's safety as a cost-effective alternative to reference bevacizumab (Avastin) for treating retinal conditions.

Eye on Pharma: CHMP Aflibercept Decision; Omalizumab Results; Dupilumab Biosimilar Deal

June 26th 2025

By Skylar Jeremias

Regulators and manufacturers advance biosimilars for aflibercept, omalizumab, and dupilumab, enhancing access to treatment in Europe and Latin America.

Cimerli Offers a New, Interchangeable Biosimilar for Ocular Conditions

May 15th 2025

By Melissa Garcia, PharmD Candidate

Cimerli offers a promising biosimilar treatment for age-related macular degeneration, enhancing vision preservation with its effective vascular endothelial growth factor inhibition.

Eye on Pharma: Interchangeability, Private Labels, and Patent Settlements for Biosimilars

May 9th 2025

By Skylar Jeremias

Ranibizumab Biosimilar Shows Reduced Efficacy vs Aflibercept in nAMD

April 3rd 2025

By Cameron Santoro

The ranibizumab biosimilar Ongavia exhibited significantly less improvement in visual acuity and retinal thickness compared with aflibercept (Eylea) in treating neovascular age-related macular degeneration (nAMD), highlighting a potential trade-off between economic savings and clinical efficacy.

Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars

March 19th 2025

By Skylar Jeremias

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, demonstrating real-world safety of biosimilar-to-biosimilar switching.

EC Approves Celltrion Denosumab, Aflibercept Biosimilars

February 20th 2025

By Skylar Jeremias

Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar (Eydenzelt).

CHMP Pushes 3 Biosimilars Forward, Spelling Hope for Ophthalmology, Supportive Care Markets

February 6th 2025

By Skylar Jeremias

The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) recommended 3 biosimilars and new indications for reference biologics, moving them closer to final European approval and expanding patient access.